Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pancreatic hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Pancreatic hormone. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-004854-29 Sponsor Protocol Number: S245.4.008 Start Date*: 2007-09-21
    Sponsor Name:Abbott Products GmbH
    Full Title: One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon® 25000 Minimicrospheres™ in subjects with pancreatic exocrine insufficiency after pancreatic sur...
    Medical condition: Pancreatic Exocrine Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-006276-16 Sponsor Protocol Number: CTRIAL-IE-20-27 Start Date*: 2022-03-09
    Sponsor Name:Cancer Trials Ireland
    Full Title: PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine.
    Medical condition: Metastatic refractory pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000682-32 Sponsor Protocol Number: PAUF-I Start Date*: 2022-02-16
    Sponsor Name:Prestige Biopharma Limited
    Full Title: A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer
    Medical condition: Advanced and/or metastatic pancreatic adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000073-24 Sponsor Protocol Number: CTRIAL-IE-19-33 Start Date*: 2020-09-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer.
    Medical condition: Advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003594-41 Sponsor Protocol Number: CSOM230c2401 Start Date*: 2008-11-26
    Sponsor Name:Uppsala University Hospital, Dept of Medical Scienses
    Full Title: An open label, multi-centre study of pasireotide LAR in addition to chemotherapy in patients with non-functioning, endocrine pancreatic tumors
    Medical condition: Non-functioning endocrine pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006209-17 Sponsor Protocol Number: I2I-MC-JMMC Start Date*: 2011-07-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer
    Medical condition: Phase I: Patients with solid malignancy unlikely to benefit from approved therapies. Phase II: Patients with pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002764-79 Sponsor Protocol Number: RESCUE Start Date*: 2023-04-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Diagnostic yield of Endoscopic aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr-) vs endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis ...
    Medical condition: Intraductal papillary mucinous intraductal neoplasia
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004864 10070999 Intraductal papillary mucinous neoplasm LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004372-36 Sponsor Protocol Number: BL-8040.PAC.201 Start Date*: 2019-05-21
    Sponsor Name:BioLineRx Ltd.
    Full Title: A phase IIa, multicenter, Open-Label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Cancer, the COMBAT study
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004150-17 Sponsor Protocol Number: 341-15 Start Date*: 2015-12-11
    Sponsor Name:Västra Götalandsregionen
    Full Title: The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
    Medical condition: Weight loss and malnutrition after curative surgery for upper gastrointestinal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003735-28 Sponsor Protocol Number: SONAZOID-PANCREAS-001 Start Date*: 2021-03-05
    Sponsor Name:Helse Bergen HF, Department of Medicine
    Full Title: The role of sonoporation-enhanced treatment with Gemcitabine, Nab-Paclitaxel and FOLFIRINOX in patients with inoperable pancreatic cancer.
    Medical condition: Histologically verified, locally advanced (nonresectable Stage II/III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000293-20 Sponsor Protocol Number: INCB18424-362 Start Date*: 2014-07-31
    Sponsor Name:Incyte Corporation
    Full Title: INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of ...
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed adenocarcinoma of the pancreas that is inoperable or metastatic.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012842-21 Sponsor Protocol Number: PR-005 Start Date*: 2010-09-20
    Sponsor Name:Aptalis Pharma US Inc.
    Full Title: Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in theTreatment of Exocrine Pancreatic Insufficien...
    Medical condition: Exocrine pancreatic insufficiency associated with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10015674 Exocrine pancreas conditions HLGT
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) BG (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-004467-13 Sponsor Protocol Number: 012255 Start Date*: 2018-10-02
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancrea...
    Medical condition: Stage IV pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-000211-64 Sponsor Protocol Number: H9H-MC-JBAJ Start Date*: 2011-07-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
    Medical condition: Phase 1b: Metastatic Cancer Phase 2: Advanced or Metastatic Unresectable Pancreatic Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004904-35 Sponsor Protocol Number: Protocol2-55-52030-726 Start Date*: 2006-08-14
    Sponsor Name:IPSEN PHARMA S.A.S.
    Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ...
    Medical condition: Non functioning entero-pancreatic tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004366-18 Sponsor Protocol Number: MAZEPPA_D19-02 Start Date*: 2020-03-03
    Sponsor Name:GERCOR
    Full Title: MAZEPPA: Phase II PRODIGE-GERCOR study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreat...
    Medical condition: Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001587-32 Sponsor Protocol Number: PANC003 Start Date*: 2019-05-07
    Sponsor Name:Rafael Pharmaceuticals, Inc
    Full Title: A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Ade...
    Medical condition: Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001589-85 Sponsor Protocol Number: D081FC00001 Start Date*: 2014-11-03
    Sponsor Name:Astrazeneca AB
    Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...
    Medical condition: Patients with gBRCA mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NL (Completed) ES (Ongoing) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005607-24 Sponsor Protocol Number: 8-79-52030-326 Start Date*: 2015-11-30
    Sponsor Name:Ipsen Innovation
    Full Title: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having ...
    Medical condition: well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) DK (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:14:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA